Sebivo fails to get health insurance

Published: 2009-03-24 07:00:00

Updated: 2009-03-24 07:00:00

Sebivo (telbivudine), a new antiviral drug used in the treatment of hepatitis infection, failed to receive health insurance benefit, according to Novartis Korea.

The Health Insurance Review and Assessment Service said on March 19 that Sevivo lacks the rationale for economic effectiveness over ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK